See more : The Nihon Seima Co.,Ltd. (3306.T) Income Statement Analysis – Financial Results
Complete financial analysis of NeutriSci International Inc. (NRXCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeutriSci International Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Sarama Resources Ltd (SRMMF) Income Statement Analysis – Financial Results
- Rion Co., Ltd. (6823.T) Income Statement Analysis – Financial Results
- Prospect Capital Corporation (0R25.L) Income Statement Analysis – Financial Results
- BioVaxys Technology Corp. (BVAXF) Income Statement Analysis – Financial Results
- PT Steadfast Marine Tbk (KPAL.JK) Income Statement Analysis – Financial Results
NeutriSci International Inc. (NRXCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neutrisci.com
About NeutriSci International Inc.
NeutriSci International Inc. develops, markets, and distributes nutraceutical products in Canada, the United States, Europe, Asia, and South America. It offers neuenergy, an energy tablet designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail and online channels. NeutriSci International Inc. has partnership with LaSanta Botanicals, Nutritional High, and Naturally Splendid. NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457.75K | 80.89K | 74.57K | 96.54K | 82.66K | 151.07K | 125.35K | 27.79K | 0.00 | 0.00 | 274.80K | 218.48K | 488.17K | 311.42K | 630.46K | 390.07K | 62.00K | 101.44K | 1.99K | 2.39K | 4.48K |
| Cost of Revenue | 501.16K | 101.44K | 80.44K | 93.60K | 78.75K | 161.73K | 99.94K | 47.72K | 0.00 | 0.00 | 116.31K | 111.16K | 324.22K | 148.85K | 0.00 | 0.00 | 83.19K | 128.07K | 1.47K | 0.00 | 0.00 |
| Gross Profit | -43.41K | -20.55K | -5.87K | 2.94K | 3.91K | -10.66K | 25.42K | -19.93K | 0.00 | 0.00 | 158.49K | 107.32K | 163.95K | 162.56K | 630.46K | 390.07K | -21.20K | -26.63K | 526.00 | 2.39K | 4.48K |
| Gross Profit Ratio | -9.48% | -25.40% | -7.87% | 3.04% | 4.73% | -7.05% | 20.28% | -71.69% | 0.00% | 0.00% | 57.68% | 49.12% | 33.58% | 52.20% | 100.00% | 100.00% | -34.19% | -26.26% | 26.39% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 458.69K | 616.49K | 598.23K | 746.35K | 894.23K | 604.31K | 261.99K | 260.01K | 264.37K | 0.00 | 0.00 |
| General & Administrative | 600.23K | 1.25M | 1.71M | 1.42M | 1.72M | 1.55M | 2.04M | 1.91M | 310.32K | 153.43K | 424.69K | 368.62K | 447.12K | 511.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -3.96K | 71.65K | 205.36K | 229.54K | 543.94K | 519.35K | 532.23K | 417.42K | 0.00 | 0.00 | 641.78K | 468.37K | 343.42K | 685.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 596.27K | 1.32M | 1.91M | 1.65M | 2.26M | 2.07M | 2.57M | 2.33M | 310.32K | 153.43K | 1.07M | 836.98K | 790.54K | 1.20M | 2.76M | 1.58M | 1.64M | 2.19M | 702.84K | 20.47K | 0.00 |
| Other Expenses | -639.68K | 24.52K | 0.00 | 0.00 | 0.00 | 28.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -43.41K | 1.37M | 1.94M | 1.65M | 2.28M | 2.08M | 2.61M | 2.35M | 310.32K | 153.43K | 1.54M | 1.47M | 1.41M | 1.97M | 3.68M | 2.20M | 1.92M | 2.50M | 981.75K | 20.47K | 19.80K |
| Cost & Expenses | 1.21M | 1.47M | 2.02M | 1.75M | 2.36M | 2.24M | 2.71M | 2.39M | 310.32K | 153.43K | 1.66M | 1.58M | 1.73M | 2.12M | 3.68M | 2.20M | 2.00M | 2.63M | 983.22K | 20.47K | 19.80K |
| Interest Income | 0.00 | 1.00K | 1.38K | 1.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.13K | 15.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.00K | 1.38K | 1.18K | 500.00 | 28.52K | 61.23K | 56.63K | 134.31K | 1.41M | 1.11M | 782.42K | 514.29K | 259.20K | 12.33K | 12.33K | 0.00 | 0.00 | 27.99K | 27.99K | 0.00 |
| Depreciation & Amortization | 37.26K | 45.11K | 27.30K | 5.04K | 3.80K | 10.44K | 15.55K | 12.48K | -620.65K | -1.71M | 15.47K | 17.07K | 19.11K | 22.90K | 24.98K | 13.92K | 14.85K | 50.11K | 14.55K | 0.00 | -30.65K |
| EBITDA | -733.43K | -1.53M | -1.92M | -1.61M | -2.36M | -2.08M | -2.49M | -3.67M | -4.93M | -310.32K | -1.37M | -74.45K | -1.35M | -1.22M | -1.78M | -3.02M | -1.81M | -1.93M | -2.48M | -966.68K | -18.08K |
| EBITDA Ratio | -160.23% | -1,630.02% | -2,570.63% | -1,705.46% | -2,729.19% | -1,360.04% | -2,050.48% | -8,470.77% | 0.00% | 0.00% | -497.33% | -616.14% | -250.90% | -571.84% | -479.04% | -460.41% | -3,106.89% | -2,446.21% | -48,503.61% | -757.71% | -342.03% |
| Operating Income | -750.58K | -1.36M | -1.94M | -1.65M | -2.26M | -2.07M | 2.59M | 2.33M | 310.32K | 1.56M | 1.38M | 1.36M | 1.24M | -1.80M | 3.05M | -1.81M | 1.94M | 2.53M | 981.23K | -18.08K | 15.32K |
| Operating Income Ratio | -163.97% | -1,685.78% | -2,607.24% | -1,710.67% | -2,733.79% | -1,366.95% | 2,062.89% | 8,383.57% | 0.00% | 0.00% | 502.96% | 623.96% | 254.81% | -579.19% | 483.00% | -463.98% | 3,130.85% | 2,495.61% | 49,233.62% | -757.71% | 342.03% |
| Total Other Income/Expenses | -20.11K | -69.49K | -8.33K | 36.71K | -7.82K | -29.02K | 21.02K | -11.00K | -3.80M | -1.87M | -3.88M | -2.55M | -3.39M | -1.24M | 0.00 | 2.50K | -42.14K | -1.94M | -2.53M | -182.09K | 18.08K |
| Income Before Tax | -770.69K | -1.57M | -1.95M | -1.61M | -2.38M | -2.12M | -2.56M | -4.01M | -389.08K | -1.56M | -2.49M | 0.00 | 0.00 | 0.00 | 0.00 | -1.81M | 1.90M | 2.29M | 0.00 | -200.17K | 0.00 |
| Income Before Tax Ratio | -168.37% | -1,943.53% | -2,618.34% | -1,670.71% | -2,882.67% | -1,404.81% | -2,046.12% | -14,411.20% | 0.00% | 0.00% | -907.23% | 0.00% | 0.00% | 0.00% | 0.00% | -463.34% | 3,062.87% | 2,258.22% | 0.00% | -8,389.40% | 0.00% |
| Income Tax Expense | 0.00 | 25.52K | 1.38K | 1.18K | 16.79K | 56.69K | 61.23K | 56.63K | 754.95K | -4.94M | -2.76M | 782.42K | 514.29K | 259.20K | -2.80K | 0.00 | 0.00 | 0.00 | 27.99K | 88.00 | 30.65K |
| Net Income | -770.69K | -1.57M | -1.95M | -1.61M | -2.38M | -2.12M | -2.56M | -4.01M | -389.08K | 7.91M | -2.49M | -2.15M | -1.76M | -2.06M | -3.04M | -1.81M | -1.98M | -2.77M | -1.01M | -200.26K | -15.32K |
| Net Income Ratio | -168.37% | -1,943.53% | -2,618.34% | -1,670.71% | -2,882.67% | -1,404.81% | -2,046.12% | -14,411.20% | 0.00% | 0.00% | -907.23% | -982.07% | -360.16% | -662.43% | -482.56% | -463.34% | -3,198.82% | -2,733.00% | -50,638.03% | -8,393.08% | -342.03% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | -0.10 | -0.05 | 2.43 | -0.77 | -0.66 | -0.54 | -0.64 | -0.98 | -0.71 | -1.52 | -3.71 | -2.30 | -2.88 | -0.11 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | -0.10 | -0.05 | 2.43 | -0.77 | -0.66 | -0.54 | -0.64 | -0.98 | -0.71 | -1.52 | -3.71 | -2.30 | -2.88 | -0.11 |
| Weighted Avg Shares Out | 166.15M | 158.59M | 143.38M | 116.02M | 101.66M | 81.83M | 59.98M | 40.61M | 7.62M | 3.26M | 3.26M | 3.26M | 3.26M | 3.22M | 3.09M | 2.54M | 1.30M | 746.79K | 439.24K | 69.44K | 138.89K |
| Weighted Avg Shares Out (Dil) | 166.15M | 158.59M | 143.38M | 116.02M | 101.66M | 81.83M | 59.98M | 40.61M | 7.62M | 3.26M | 3.26M | 3.26M | 3.26M | 3.22M | 3.09M | 2.54M | 1.30M | 746.79K | 439.24K | 69.44K | 138.89K |
NeutriSci Receives Additional Purchase Order and Deposit from Tabletz Distribution Partner
VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it...
NeutriSci Arranges Strategic Financing with Tabletz and Exercise of Warrants
VANCOUVER, BC / ACCESSWIRE / September 10, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products, licencing IP, and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it...
Neutrisci Provides Update on Tabletz Developments
VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to provide an update...
Neutrisci Provides Update on Tabletz and Previously Announced Project Development
VANCOUVER, BC / ACCESSWIRE / July 7, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licensing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to provide an update...
NeutriSci Provides Update On Biople Product Launch In Japan
VANCOUVER, BC / ACCESSWIRE / June 23, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU) (OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with its partner, Tabletz LLC, is pleased to update details...
Neutrisci Ships Tabletz Rush Order to #1 CBD Retailer in Japan
VANCOUVER, BC / ACCESSWIRE / June 9, 2021 / NeutriSci International Inc. ('NeutriSci' or the 'Company') (TSXV:NU)(OTCQB:NRXCF)(FSE:1N9), an innovative technology company developing products, licensing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce that it...
NeutriSci Completes R&D and Expands Product Selection to Include Beverages
VANCOUVER, BC / ACCESSWIRE / May 27, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU, OTCQB:NRXCF, FRANKFURT: 1N9), an innovative technology company developing products, licensing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to...
NeutriSci and Pacwest Announce Technology and IP Arrangement for R&D Product Development
VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to announce the completion of...
Neutrisci Announces Successful Completion of Phase 1 R&D Development of a Cannabinol Product
VANCOUVER, BC / ACCESSWIRE / May 10, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce the Phase 1 R&D...
Neutrisci Receives Additional Order for Japanese Market
VANCOUVER, BC / ACCESSWIRE / May 3, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FSE:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to announce that Tabletz LLC. has placed an additional order for...
Source: https://incomestatements.info
Category: Stock Reports